Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | CES1 | P23141 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18377357 | 0.73 | TRPV4 (0.46) | TRPV4CA1CA12 | |
| SCHEMBL13236550 | 0.73 | TRPV4 (0.46) | TRPV4 | |
| SCHEMBL23699469 | 0.72 | CES2 (0.43) | TRPV4CES2CES1CA1CA2 | |
| SCHEMBL17550029 | 0.71 | CES2 (0.41) | CES2CES1CA1CA2CA4 | |
| SCHEMBL48385 | 0.71 | CA1 (0.38) | TRPV4CES2CES1CA1CA2 | |
| SCHEMBL1525706 | 0.69 | CES2 (0.45) | CES2CES1CA1CA2CA4 | |
| SCHEMBL531337 | 0.69 | CES2 (0.52) | CES2CES1CA1CA2CA4 | |
| SCHEMBL50484 | 0.69 | TRPV4 (0.42) | TRPV4 | |
| SCHEMBL28208517 | 0.69 | CA1 (0.36) | TRPV4CES2CES1CA1CA2 | |
| SCHEMBL24925253 | 0.67 | TRPV4 (0.41) | TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2021226629-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210007356-A1 | IMIDE DERIVATIVE AND FUNGICIDE CONTAINING SAID DERIVATIVE AS ACTIVE INGREDIENT | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2021-01-14 | — | — | US | disclosed |
| EP-3760627-A1 | IMIDE DERIVATIVE AND BACTERICIDE CONTAINING SAME AS ACTIVE INGREDIENT | Hokko Chemical Industry Co., Ltd. (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-10820591-B2 | Substituted sulfonyl amides for controlling animal pests | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-03 | — | — | US | disclosed |
| WO-2020211798-A1 | INHIBITOR CONTAINING BICYCLIC RING DERIVATIVE, AND PREPARATION METHOD AND USES THEREFOR | 上海翰森生物医药科技有限公司 | 2020-10-22 | — | — | WO | disclosed |
| EP-2841433-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL CO (JP) | 2017-06-21 | — | — | EP | disclosed |
| US-9565856-B2 | Tetrazolinone compounds and its use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9380782-B2 | Tetrazolinone compounds and its use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-05 | — | — | US | disclosed |
| US-20150051171-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| US-20150031733-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | TRPV4 4185/4885CES2 4730/4885CES1 1773/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | TRPV4 3020/4885CES2 2243/4885CES1 2325/4885 |
| US-20150031733-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | CBR3, CYP51A1, CYP8B1 | TRPV4 1496/4885CES2 2350/4885CES1 1829/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | TRPV4 4185/4885CES2 4730/4885CES1 1773/4885 |
| US-20210007356-A1 | IMIDE DERIVATIVE AND FUNGICIDE CONTAINING SAID DERIVATIVE AS ACTIVE INGREDIENT | CYP51A1, DDT, CYP1A1 | TRPV4 1977/4885CES2 897/4885CES1 915/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | TRPV4 4185/4885CES2 4730/4885CES1 1773/4885 |
| US-10820591-B2 | Substituted sulfonyl amides for controlling animal pests | MLYCD, STOM, DDT | TRPV4 4039/4885CES2 680/4885CES1 528/4885 |
| US-20150051171-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | CBR3, CYCS, CBR1 | TRPV4 786/4885CES2 1927/4885CES1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.